Related Experiment Video

Updated: Jul 21, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Exosomal non-coding RNAs-mediated EGFR-TKIs resistance in NSCLC with EGFR mutation

Daoan Cheng1, Banglu Wang1, Lige Wu1

  • 1Departments of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, 213004, China.

Medical Oncology (Northwood, London, England)
|July 28, 2023
PubMed

Insights

Exosomes carrying non-coding RNAs (ncRNAs) drive resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Targeting these exosomal ncRNAs may overcome EGFR-TKI resistance in lung cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have improved outcomes for EGFR-mutant non-small cell lung cancer (NSCLC).
  • Acquired resistance to EGFR-TKIs remains a significant clinical challenge in NSCLC treatment.

Purpose of the Study:

  • To review the role of exosomal non-coding RNAs (ncRNAs) in mediating resistance to EGFR-TKIs in EGFR-mutated NSCLC.
  • To provide a comprehensive overview of current research on this topic.
  • To highlight the potential of exosomal ncRNAs as biomarkers and therapeutic targets.

Main Methods:

  • Literature review of studies investigating exosomal ncRNAs and EGFR-TKI resistance in NSCLC.
  • Analysis of findings on circular RNAs (circRNAs), microRNAs (miRNAs), and long noncoding RNAs (lncRNAs) within exosomes.
  • Synthesis of information on the mechanisms by which these ncRNAs contribute to resistance.

Main Results:

  • Exosomes facilitate intercellular transfer of ncRNAs, including circRNA, miRNA, and lncRNA.
  • These exosomal ncRNAs play a crucial role in the development and progression of EGFR-TKI resistance in NSCLC.
  • Specific exosomal ncRNAs have been identified as key mediators of resistance pathways.

Conclusions:

  • Exosomal ncRNAs are critical players in EGFR-TKI resistance in EGFR-mutated NSCLC.
  • Detection of exosomal ncRNAs could serve as a monitoring tool for targeted therapy efficacy in NSCLC.
  • Targeting exosomal ncRNAs presents a promising therapeutic strategy to overcome resistance and improve clinical outcomes for NSCLC patients.
Keywords:
EGFR-TKIsExosomeLung cancerResistancencRNAs

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K